Trade Surface Oncology - SURF CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.05 |
| Open | 1.02 |
| 1-Year Change | -21.54% |
| Day's Range | 0.99 - 1.05 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 7, 2023 | 1.05 | 0.03 | 2.94% | 1.02 | 1.05 | 0.99 |
| Sep 6, 2023 | 1.05 | 0.07 | 7.14% | 0.98 | 1.08 | 0.98 |
| Sep 5, 2023 | 0.99 | -0.06 | -5.71% | 1.05 | 1.05 | 0.98 |
| Sep 1, 2023 | 1.06 | 0.02 | 1.92% | 1.04 | 1.08 | 1.02 |
| Aug 31, 2023 | 1.05 | 0.03 | 2.94% | 1.02 | 1.06 | 1.01 |
| Aug 30, 2023 | 1.04 | 0.02 | 1.96% | 1.02 | 1.06 | 1.02 |
| Aug 29, 2023 | 1.03 | 0.07 | 7.29% | 0.96 | 1.04 | 0.96 |
| Aug 28, 2023 | 0.98 | 0.03 | 3.16% | 0.95 | 0.98 | 0.92 |
| Aug 25, 2023 | 0.93 | 0.02 | 2.20% | 0.91 | 0.93 | 0.91 |
| Aug 24, 2023 | 0.93 | 0.02 | 2.20% | 0.91 | 0.93 | 0.89 |
| Aug 23, 2023 | 0.92 | 0.00 | 0.00% | 0.92 | 0.96 | 0.92 |
| Aug 22, 2023 | 0.89 | -0.01 | -1.11% | 0.90 | 0.92 | 0.87 |
| Aug 21, 2023 | 0.90 | 0.02 | 2.27% | 0.88 | 0.92 | 0.87 |
| Aug 18, 2023 | 0.88 | 0.05 | 6.02% | 0.83 | 0.89 | 0.83 |
| Aug 17, 2023 | 0.86 | -0.02 | -2.27% | 0.88 | 0.89 | 0.85 |
| Aug 16, 2023 | 0.88 | -0.01 | -1.12% | 0.89 | 0.90 | 0.88 |
| Aug 15, 2023 | 0.89 | 0.01 | 1.14% | 0.88 | 0.89 | 0.86 |
| Aug 14, 2023 | 0.88 | -0.02 | -2.22% | 0.90 | 0.91 | 0.87 |
| Aug 11, 2023 | 0.91 | -0.01 | -1.09% | 0.92 | 0.92 | 0.90 |
| Aug 10, 2023 | 0.92 | 0.02 | 2.22% | 0.90 | 0.94 | 0.90 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Surface Oncology Company profile
About Surface Oncology Inc
Surface Oncology, Inc. is a clinical-stage, immuno-oncology company focused on developing antibody therapies focused on the tumor microenvironment. The Company is developing multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Its pipeline includes two wholly owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a pre-clinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with pharmaceutical companies, including a collaboration with Novartis targeting CD73 (NZV930; Phase I) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Surface Oncology Inc revenues decreased 98% to $2.7M. Net loss totaled $78.5M vs. income of $59.3M. Revenues reflect License-related revenue decrease of 97% to $2.7M, Collaboration revenue - related party decrease from $38.6M to $0K. Net loss reflects Research and development - Balancing increase of 34% to $48.5M (expense), Stock-based Compensation in SGA increase of 24% to $6.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
50 Hampshire Street, 8Th Floor
CAMBRIDGE
MASSACHUSETTS 02139
US
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com